AQST vs SPRB
AQST: Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film platforms. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | AQST | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.73 | $41.99 | |
| Market cap as of 2026-07-31 | $468M | $116M | |
| PEG as of 2026-07-31 | -1.81 | n/a | |
| Net margin as of 2026-07-31 | -137.1% | -1079.9% | AQST higher |
| Gross margin as of 2026-07-31 | +63.5% | n/a | |
| Operating margin as of 2026-07-31 | -111.2% | -1143.4% | AQST higher |
| ROE as of 2026-07-31 | -21.8% | -155.4% | AQST higher |
| ROA as of 2026-07-31 | -49.3% | -101.7% | AQST higher |
| Debt / equity as of 2026-07-31 | 4.68 | 0.19 | SPRB lower |
| Revenue growth (YoY) as of 2026-07-31 | -7.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -2.2% | n/a | |
| Beta as of 2026-07-31 | 1.47 | 3.51 | |
| 1-year return as of 2026-07-27 close | -10.1% | n/a |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.